Clovis Oncology has announced the beginning of the first clinical study of the company's experimental oncology product CO-1686 with the dosing of the first patient at a study site in the US.
CO-1686 is a novel, oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations being explored as a treatment of non-small cell lung cancer (NSCLC).
Clovis envisions this agent as being suitable for NSCLC patients who have failed prior EGFR-directed treatments including Tarceva or Iressa and have developed the dominant resistance mechanism to those drugs, the T790M mutation.
CO-1686 is a targeted covalent (irreversible) inhibitor of EGFR mutations, designed to selectively target both the initial activating EGFR mutations as well as the T790M resistance mutation, while sparing“normal” EGFR. Ideally, it will cut down on the number of primary toxicities induced by other EGFR inhibitors while still causing tumor shrinkage.
Source: Therapeutics Daily
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
